Key Points
The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date.
Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.
The insider maintains equity exposure through 580,000 direct derivative securities in the form of stock options following this filing.
David Tsao, co-founder and Chief Technology Officer of BillionToOne, Inc. (NASDAQ:BLLN), sold 10,000 shares of Class A Common Stock on August 25, 2026, as disclosed in an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 10,000 |
| Transaction value | $1.0 million |
| Post-transaction shares (directly held) | 1,000 |
| Post-transaction value | $100,080.00 |
Transaction value based on SEC Form 4 weighted average sale price ($100.00); post-transaction value based on August 25, 2026 market close ($100.08).
Key questions
- What was the structural nature of this transaction?
David Tsao executed a cashless exercise of 10,000 fully vested stock options with an exercise price of $2.80 and concurrently sold the resulting Class A Common Stock at a weighted-average price of $100.00. - How does this disposal impact the insider's total equity alignment?
While the direct common stock position is now 1,000 shares, the reporting owner retains 580,000 stock options, ensuring that his financial interests remain tied to the performance of BillionToOne. - Does the timing of the sale reflect a discretionary response to market conditions?
The transaction was carried out under a Rule 10b5-1 trading plan adopted on March 6, 2026, which indicates the sale was scheduled under pre-established parameters set months prior to execution. - What is the current market valuation of the company's stock?
BillionToOne Class A Common Stock was priced at $96.22 as of the August 26, 2026 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-26) | $96.22 |
| Market Capitalization | $4.4 billion |
| Revenue (TTM) | $397.4 million |
| Net Income (TTM) | $33.5 million |
Company Snapshot
- BillionToOne develops advanced molecular diagnostic solutions leveraging its proprietary molecular counting platform to identify and measure individual DNA molecules, with key products including UNITY Complete, a non-invasive prenatal screening test that assesses fetal risk for chromosomal abnormalities.
- The company operates a precision diagnostics business model that generates revenue through the delivery of molecular diagnostic testing services and solutions to healthcare providers, laboratories, and patients seeking enhanced disease detection accuracy.
- BillionToOne serves healthcare systems, diagnostic laboratories, and medical care providers globally, targeting clinicians and patients who require high-precision molecular diagnostic capabilities for improved clinical decision-making.
BillionToOne is a specialized diagnostics company with a market cap of $4.4 billion, operating from its Menlo Park headquarters. The company has demonstrated profitability with trailing 12-month net income of $33.5 million on revenue of $397.4 million, reflecting strong operational execution in the precision diagnostics market.
BillionToOne's competitive differentiation stems from its proprietary molecular counting platform technology, which enables unprecedented precision in DNA molecule identification and measurement, positioning the company as an innovator in molecular diagnostics.
What this transaction means for investors
The Aug. 25 sale of BillionToOne stock by the company's CTO, David Tsao, took place after shares had fallen from a 52-week high of $150.44 on Aug. 5. Even so, the move does not necessarily reflect the insider's view on the stock, since this was a non-discretionary transaction arranged in advance through a Rule 10b5-1 trading plan.
Such plans allow insiders to sell shares at predetermined times to avoid concerns of trading on non-public information. Tsao also retains 580,000 stock options post-sale, indicating that he maintains a substantial equity stake in the company he co-founded.
BillionToOne stock declined after the company announced second-quarter earnings on Aug. 5. It reiterated revenue guidance for full year 2026, which disappointed Wall Street investors after shares had reached a lofty valuation.
Despite the share price drop, Q2 revenue hit $109.4 million, an impressive 64% year-over-year increase as its prenatal and oncology tests experienced strong sales growth. This demonstrates BillionToOne continues to see robust demand for its services.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BillionToOne. The Motley Fool has a disclosure policy.